A phase IV, multi-center, open-label, safety and effectiveness study of extended-release carbamazepine in the treatment of mania in children and adolescents aged 10-17 years with acute manic or mixed bipolar I disorder

Trial Profile

A phase IV, multi-center, open-label, safety and effectiveness study of extended-release carbamazepine in the treatment of mania in children and adolescents aged 10-17 years with acute manic or mixed bipolar I disorder

Completed
Phase of Trial: Phase IV

Latest Information Update: 19 Apr 2014

At a glance

  • Drugs Carbamazepine (Primary)
  • Indications Bipolar I disorders
  • Focus Adverse reactions
  • Sponsors Validus Pharmaceuticals
  • Most Recent Events

    • 01 May 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 07 Oct 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top